Gain Capital Surpluse vs Net Receivables Analysis

GANX Stock

USD 2.73 0.17 6.64%

Gain Therapeutics financial indicator trend analysis is much more than just examining Gain Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gain Therapeutics is a good investment. Please check the relationship between Gain Therapeutics Capital Surpluse and its Net Receivables accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Capital Surpluse vs Net Receivables

Capital Surpluse vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gain Therapeutics Capital Surpluse account and Net Receivables. At this time, the significance of the direction appears to have pay attention.

The correlation between Gain Therapeutics' Capital Surpluse and Net Receivables is -0.78. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Gain Therapeutics, assuming nothing else is changed. The correlation between historical values of Gain Therapeutics' Capital Surpluse and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Gain Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Capital Surpluse i.e., Gain Therapeutics' Capital Surpluse and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Capital Surpluse

Net Receivables

Most indicators from Gain Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 13 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 3.4 M in 2025.

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	64.2K	78.1K	89.8K	94.3K
Total Operating Expenses	17.9M	22.3M	25.7M	26.9M

Reconciled Depreciation Total Operating Expenses

Gain Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total
Other Current Liab		1.0	0.71	0.79	-0.98	0.9	0.81	0.94	0.85	0.96	0.99	0.77	0.98	-0.2	0.8	0.83	0.74	0.82	0.71	-0.53	0.61	0.73	0.86	0.78	0.97	0.82
Total Current Liabilities	1.0		0.7	0.76	-0.98	0.89	0.8	0.96	0.86	0.97	0.98	0.74	0.98	-0.22	0.77	0.81	0.7	0.79	0.75	-0.51	0.59	0.68	0.86	0.75	0.96	0.81
Other Liab	0.71	0.7		0.92	-0.64	0.65	0.86	0.6	0.8	0.62	0.76	0.93	0.73	0.47	0.93	0.92	0.92	0.93	0.29	-0.9	0.92	0.61	0.86	0.93	0.8	0.93
Net Tangible Assets	0.79	0.76	0.92		-0.75	0.74	0.84	0.67	0.72	0.72	0.85	0.99	0.82	0.38	0.99	0.92	0.98	0.96	0.35	-0.91	0.93	0.7	0.85	0.99	0.89	0.92
Retained Earnings	-0.98	-0.98	-0.64	-0.75		-0.88	-0.74	-0.95	-0.82	-0.97	-0.97	-0.71	-0.97	0.27	-0.74	-0.74	-0.67	-0.74	-0.77	0.49	-0.56	-0.65	-0.79	-0.73	-0.94	-0.75
Accounts Payable	0.9	0.89	0.65	0.74	-0.88		0.87	0.75	0.86	0.79	0.85	0.71	0.83	-0.19	0.73	0.83	0.66	0.78	0.46	-0.43	0.49	0.79	0.89	0.7	0.85	0.81
Other Assets	0.81	0.8	0.86	0.84	-0.74	0.87		0.68	0.85	0.69	0.8	0.84	0.77	0.25	0.84	0.97	0.8	0.9	0.36	-0.7	0.74	0.66	1.0	0.82	0.81	0.97
Net Receivables	0.94	0.96	0.6	0.67	-0.95	0.75	0.68		0.77	0.99	0.95	0.64	0.97	-0.25	0.67	0.68	0.6	0.66	0.9	-0.47	0.55	0.46	0.74	0.66	0.9	0.7
Common Stock Shares Outstanding	0.85	0.86	0.8	0.72	-0.82	0.86	0.85	0.77		0.78	0.83	0.69	0.81	-0.09	0.71	0.8	0.64	0.74	0.54	-0.5	0.56	0.59	0.86	0.69	0.8	0.81
Other Current Assets	0.96	0.97	0.62	0.72	-0.97	0.79	0.69	0.99	0.78		0.97	0.69	0.99	-0.25	0.72	0.71	0.66	0.71	0.85	-0.5	0.58	0.56	0.75	0.71	0.94	0.72
Other Stockholder Equity	0.99	0.98	0.76	0.85	-0.97	0.85	0.8	0.95	0.83	0.97		0.83	1.0	-0.09	0.85	0.84	0.8	0.85	0.72	-0.64	0.71	0.69	0.85	0.84	0.99	0.84
Total Current Assets	0.77	0.74	0.93	0.99	-0.71	0.71	0.84	0.64	0.69	0.69	0.83		0.8	0.43	1.0	0.93	0.99	0.98	0.3	-0.93	0.95	0.72	0.84	1.0	0.88	0.93
Common Stock	0.98	0.98	0.73	0.82	-0.97	0.83	0.77	0.97	0.81	0.99	1.0	0.8		-0.12	0.82	0.81	0.77	0.82	0.77	-0.61	0.68	0.65	0.82	0.81	0.98	0.81
Property Plant Equipment	-0.2	-0.22	0.47	0.38	0.27	-0.19	0.25	-0.25	-0.09	-0.25	-0.09	0.43	-0.12		0.39	0.33	0.46	0.36	-0.4	-0.68	0.63	-0.04	0.19	0.41	-0.01	0.36
Total Assets	0.8	0.77	0.93	0.99	-0.74	0.73	0.84	0.67	0.71	0.72	0.85	1.0	0.82	0.39		0.94	0.99	0.99	0.32	-0.91	0.94	0.76	0.85	1.0	0.9	0.93
Short Long Term Debt Total	0.83	0.81	0.92	0.92	-0.74	0.83	0.97	0.68	0.8	0.71	0.84	0.93	0.81	0.33	0.94		0.92	0.98	0.33	-0.81	0.85	0.75	0.97	0.93	0.87	1.0
Total Stockholder Equity	0.74	0.7	0.92	0.98	-0.67	0.66	0.8	0.6	0.64	0.66	0.8	0.99	0.77	0.46	0.99	0.92		0.98	0.25	-0.94	0.95	0.74	0.81	1.0	0.86	0.91
Property Plant And Equipment Net	0.82	0.79	0.93	0.96	-0.74	0.78	0.9	0.66	0.74	0.71	0.85	0.98	0.82	0.36	0.99	0.98	0.98		0.3	-0.87	0.9	0.8	0.9	0.98	0.9	0.96
Current Deferred Revenue	0.71	0.75	0.29	0.35	-0.77	0.46	0.36	0.9	0.54	0.85	0.72	0.3	0.77	-0.4	0.32	0.33	0.25	0.3		-0.2	0.28	0.07	0.44	0.32	0.63	0.38
Net Debt	-0.53	-0.51	-0.9	-0.91	0.49	-0.43	-0.7	-0.47	-0.5	-0.5	-0.64	-0.93	-0.61	-0.68	-0.91	-0.81	-0.94	-0.87	-0.2		-0.99	-0.47	-0.69	-0.93	-0.7	-0.83
Cash	0.61	0.59	0.92	0.93	-0.56	0.49	0.74	0.55	0.56	0.58	0.71	0.95	0.68	0.63	0.94	0.85	0.95	0.9	0.28	-0.99		0.5	0.74	0.95	0.76	0.87
Non Current Assets Total	0.73	0.68	0.61	0.7	-0.65	0.79	0.66	0.46	0.59	0.56	0.69	0.72	0.65	-0.04	0.76	0.75	0.74	0.8	0.07	-0.47	0.5		0.68	0.72	0.76	0.68
Non Currrent Assets Other	0.86	0.86	0.86	0.85	-0.79	0.89	1.0	0.74	0.86	0.75	0.85	0.84	0.82	0.19	0.85	0.97	0.81	0.9	0.44	-0.69	0.74	0.68		0.84	0.85	0.98
Cash And Short Term Investments	0.78	0.75	0.93	0.99	-0.73	0.7	0.82	0.66	0.69	0.71	0.84	1.0	0.81	0.41	1.0	0.93	1.0	0.98	0.32	-0.93	0.95	0.72	0.84		0.89	0.92
Common Stock Total Equity	0.97	0.96	0.8	0.89	-0.94	0.85	0.81	0.9	0.8	0.94	0.99	0.88	0.98	-0.01	0.9	0.87	0.86	0.9	0.63	-0.7	0.76	0.76	0.85	0.89		0.87
Non Current Liabilities Total	0.82	0.81	0.93	0.92	-0.75	0.81	0.97	0.7	0.81	0.72	0.84	0.93	0.81	0.36	0.93	1.0	0.91	0.96	0.38	-0.83	0.87	0.68	0.98	0.92	0.87

Click cells to compare fundamentals

Gain Therapeutics Account Relationship Matchups

Gain Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	767.4K	1.2M	2.0M	2.1M	2.4M	2.5M
Total Current Liabilities	2.1M	2.6M	4.1M	4.9M	5.7M	6.0M
Other Liab	132.2K	171.6K	329.5K	157.6K	181.2K	179.3K
Net Tangible Assets	(450.0K)	6.2M	34.6M	18.7M	21.5M	12.8M
Retained Earnings	(7.0M)	(20.9M)	(38.5M)	(60.8M)	(54.7M)	(52.0M)
Accounts Payable	961.5K	560.5K	1.6M	1.3M	1.5M	874.7K
Other Assets	11.4K	63.8K	53.4K	48.3K	55.6K	41.4K
Net Receivables	66.6K	113.6K	103.9K	242.6K	279.0K	292.9K
Other Current Assets	71.0K	343.1K	399.8K	741.6K	852.9K	895.5K
Other Stockholder Equity	13.4M	55.8M	57.4M	73.1M	84.1M	88.3M
Total Current Assets	9.0M	37.7M	21.1M	17.8M	20.4M	15.9M
Property Plant Equipment	219.3K	552.7K	1.0M	144.4K	166.0K	157.7K
Total Assets	9.6M	39.0M	24.1M	18.6M	21.4M	20.2M
Short Long Term Debt Total	1.3M	1.6M	1.3M	1.0M	1.2M	1.2M
Total Stockholder Equity	6.2M	34.8M	18.9M	12.6M	14.5M	15.8M
Property Plant And Equipment Net	552.7K	1.0M	804.3K	585.2K	673.0K	697.1K
Current Deferred Revenue	239.5K	266.5K	55.2K	1.1M	1.3M	1.4M
Net Debt	(6.2M)	(35.3M)	(6.0M)	(10.8M)	(9.7M)	(10.2M)
Cash	7.5M	36.9M	7.3M	11.8M	13.6M	14.0M
Non Current Assets Total	616.5K	1.3M	3.0M	830.5K	955.0K	1.3M
Non Currrent Assets Other	63.8K	53.4K	48.3K	51.9K	59.7K	48.1K
Cash And Short Term Investments	7.5M	36.9M	20.1M	16.8M	19.3M	18.0M
Liabilities And Stockholders Equity	9.6M	39.0M	24.1M	18.6M	21.4M	20.2M
Non Current Liabilities Total	1.3M	1.6M	1.1M	1.1M	1.2M	1.2M
Capital Lease Obligations	523.1K	914.2K	670.9K	459.5K	528.5K	609.1K
Total Liab	3.4M	4.2M	5.2M	6.0M	6.9M	4.4M
Net Invested Capital	6.9M	35.5M	19.5M	13.1M	15.1M	16.4M
Property Plant And Equipment Gross	552.7K	1.0M	804.3K	678.0K	779.7K	717.5K
Accumulated Other Comprehensive Income	(152.7K)	(90.6K)	35.6K	247.2K	284.3K	298.5K
Net Working Capital	6.9M	35.2M	17.0M	12.8M	14.8M	15.7M
Short Term Debt	145.4K	542.1K	337.2K	348.5K	400.8K	324.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gain Capital Surpluse vs Net Receivables Analysis

Capital Surpluse vs Net Receivables

Capital Surpluse vs Net Receivables Correlation Analysis

Correlation Coefficient

Capital Surpluse

Net Receivables

Gain Therapeutics fundamental ratios Correlations

Gain Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gain Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Gain Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Non Currrent Assets Other	+ 1.0	Other Assets
Common Stock	+ 1.0	Other Stockholder Equity
Total Assets	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash	- 0.99	Net Debt
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Common Stock	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings